摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(1,7-dioxa-2-aza-spiro[4.4]non-2-en-3-yl)-2-methoxy-phenol | 847675-39-2

中文名称
——
中文别名
——
英文名称
5-(1,7-dioxa-2-aza-spiro[4.4]non-2-en-3-yl)-2-methoxy-phenol
英文别名
5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxy-phenol;5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenol
5-(1,7-dioxa-2-aza-spiro[4.4]non-2-en-3-yl)-2-methoxy-phenol化学式
CAS
847675-39-2
化学式
C13H15NO4
mdl
——
分子量
249.266
InChiKey
SIOUFXKDRPZOCN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    421.2±55.0 °C(Predicted)
  • 密度:
    1.36±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    60.3
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Isoxazolines and their use as inhibitors of phosphodiesterase type-IV
    申请人:Ranbaxy Laboratories Limited
    公开号:EP1840123A1
    公开(公告)日:2007-10-03
    The present invention relates to isoxazoline derivatives of formula I, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.
    本发明涉及公式I的异噁唑啉衍生物,可用作选择性磷酸二酯酶(PDE)IV型抑制剂。特别是,本文披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺病(COPD)、牛皮癣、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合征(ARDS)、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病的治疗,尤其是在人类患者中。本发明还涉及所述化合物的制备方法,以及其药物组合物和作为磷酸二酯酶(PDE)IV型抑制剂的用途。
  • INHIBITORS OF PHOSPHODIESTERASE TYPE-IV
    申请人:Rudra Sonali
    公开号:US20110021473A1
    公开(公告)日:2011-01-27
    The present invention relates to catechol derivatives of formula (I), which can be used as inhibitors of phosphodiesterase (PDPI) type 4 or type 7, Compounds disclosed herein can be useful in the treatment of CNS disorders, inflammatory diseases such as, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type 4 or type 7 inhibitors.
    本发明涉及公式(I)的邻苯二酚衍生物,可用作磷酸二酯酶(PDPI)类型4或类型7的抑制剂。本文披露的化合物可用于治疗中枢神经系统疾病、炎症性疾病,如艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺病(COPD)、牛皮癣、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合征(ARDS)、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病,尤其是在人类身上。提供了用于制备所述化合物的方法,以及含有所述化合物的药物组合物,以及它们作为磷酸二酯酶(PDE)类型4或类型7抑制剂的用途。
  • Inhibitors of phophodiesterase type-IV
    申请人:Palle P. Venkata
    公开号:US20050075383A1
    公开(公告)日:2005-04-07
    The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.
    本发明涉及异噁唑啉衍生物,可用作选择性磷酸二酯酶(PDE)IV型抑制剂。特别是,所披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺疾病(COPD)、银屑病、过敏性鼻炎、休克、特应性皮炎、克隆病、成人呼吸窘迫综合症(ARDS)、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病的患者,特别是人类。本发明还涉及所披露化合物的制备方法,以及其作为磷酸二酯酶(PDE)IV型抑制剂的药物组合物和用途。
  • CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE - IV
    申请人:Palle Venkata P.
    公开号:US20090048247A1
    公开(公告)日:2009-02-19
    The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.
    本发明涉及异噁唑啉衍生物,可用作选择性磷酸二酯酶(PDE)IV型抑制剂。特别地,本文所披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺疾病(COPD)、银屑病、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合症(ARDS)、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病的患者,特别是人类。本发明还涉及所披露的化合物的制备方法,以及其作为磷酸二酯酶(PDE)IV型抑制剂的药物组合物及其应用。
  • Inhibitors of phosphodiesterase type-IV
    申请人:Ranbaxy Laboratories Limited
    公开号:US07825147B2
    公开(公告)日:2010-11-02
    The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.
    本发明涉及异硝嗪衍生物,可用作磷酸二酯酶(PDE)IV型的选择性抑制剂。具体而言,本文所披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺疾病(COPD)、牛皮癣、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合征(ARDS)、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病的治疗,特别是在人类患者中。本发明还涉及所披露的化合物的制备方法、以及其作为磷酸二酯酶(PDE)IV型抑制剂的药物组合物和使用方法。
查看更多